Global incidence of multidrug-resistant tuberculosis.
暂无分享,去创建一个
Mehran Hosseini | Brian G. Williams | Christopher Dye | Paul Nunn | C. Dye | B. Williams | M. Hosseini | P. Nunn | M. Zignol | Matteo Zignol | A Wright | Catharina Lambregts–van Weezenbeek | Catherine J. Watt | C. Watt | A. Wright | C. L. Weezenbeek | C. V. Weezenbeek | Mehran Hosseini | B. Williams
[1] T. Chou,et al. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance , 2004, Nature Medicine.
[2] Rajesh K. Gupta,et al. Responding to Market Failures in Tuberculosis Control , 2001, Science.
[3] F. Cobelens,et al. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[4] Lung Disease,et al. Anti-tuberculosis drug resistance in the world : the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance , 1997 .
[5] Global Tuberculosis Programme. Global tuberculosis control : WHO report , 1997 .
[6] M. Uplekar,et al. WHO's new Stop TB Strategy , 2006, The Lancet.
[7] C. Dye,et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru , 2002, The Lancet.
[8] C. Dye,et al. Worldwide incidence of multidrug-resistant tuberculosis. , 2002, The Journal of infectious diseases.
[9] M. Espinal,et al. Increasing transparency in partnerships for health – introducing the Green Light Committee , 2002, Tropical medicine & international health : TM & IH.
[10] M. Aziz,et al. Guidelines for surveillance of drug resistance in tuberculosis , 2009 .